EMA will accept biosimilar reference products sourced outside EEA, but not immediately
This article was originally published in Scrip
Executive Summary
In a major policy shift, the European Medicines Agency says it will accept batches of reference medicines for biosimilars sourced from outside the European Economic Area in certain pre-clinical and clinical studies for the comparability exercise when considering biosimilar applications made under the centralised procedure.